Sight Sciences

Sight Sciences, Inc. is a medical device company, which engages in the provision of glaucoma implants for treatment of irreversible blindness. It also develops pharmaceuticals, drug delivery systems, and diagnostics for the treatment of ophthalmic conditions. The firm's products include viscosurgical system and trabeculotomy instruments. It operates through the Surgical Glaucoma and Dry Eye segments. The Surgical Glaucoma segment includes OMNI Surgical System for use in minimally invasive glaucoma procedures. The Dry Eye segment offers TearCare System and related components. The company was founded by Paul Badawi and David Y. Badawi in 2011 and is headquartered in Menlo Park, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sight Sciences reports stellar Q4 earnings, eyes sustainable growth

Sight Sciences delivered strong revenue growth in Q4 2022, driven by successful product offerings and market expansion efforts. While facing increased operating expenses and margin challenges, the company remains optimistic about achieving cash flow breakeven by 2025 and sustaining growth through innovative technologies and market strategies.

Sight Sciences excels in Q1 earnings, eyes growth opportunities

Sight Sciences' Q1 2023 performance reflects strong revenue growth, effective cost management, and a clear path towards achieving financial targets.
The company's leadership reinforcement, strategic focus on cash flow, and discussions on market trends position it well for future success.
While facing challenges in reimbursement changes and operational efficiency, Sight Sciences is poised to leverage opportunities for innovation and growth.

Sight Sciences excels in Q2 with record revenue and clinical validation

Sight Sciences demonstrated strong financial performance, highlighted by revenue growth and operational improvements. While facing challenges related to potential impacts on product sales and reimbursement discussions, the company remains optimistic about the growth prospects of its innovative technologies and reaffirmed its annual revenue guidance.

Sight Sciences reports Q3 revenue growth amidst operational improvements

Sight Sciences delivered solid financial performance in Q3, with revenue growth, margin improvement, and cost-saving measures
While facing challenges related to market access and revenue uncertainties, the company's strengths in innovation and efficiency position it well for future growth
Strategic opportunities in product development, market expansion, and operational optimization can drive sustained success and value creation for stakeholders

Sight Sciences posts successful Q4 results amidst revenue challenges

Sight Sciences reported strong financial performance in Q4 2023, with revenue growth, improved margins, and reduced expenses.
The company faces challenges in revenue decline for Q4, optimizing commercial strategies, and navigating reimbursement landscapes.
Opportunities lie in market expansion, revenue growth, reimbursement wins, and shifting treatment paradigms towards minimally invasive interventions.
Overall, Sight Sciences is well-positioned with a focus on innovation, clinical efficacy, and commercial strategies for 2024 opportunities.

Sight Sciences reports record Q1 revenue and eyes sustained growth

Sight Sciences posted strong financials with record revenue and improved cash usage.
Focused on driving growth in Surgical Glaucoma and addressing challenges in Dry Eye market.
Opportunities lie in market expansion, technology adoption, and sustained growth.
Company optimistic about achieving double-digit growth in the coming quarters.

Sight Sciences reports strong Q2 results, eyes growth opportunities ahead

Sight Sciences demonstrated robust financial and operational performance in Q2 2024, driven by revenue growth and improved cash management.
Strategic initiatives in surgeon training, product differentiation, and pricing reflect the company's focus on market expansion and value realization.
While facing challenges in revenue outlook and market dynamics, Sight Sciences remains poised to capitalize on growth opportunities in both Surgical Glaucoma and Dry Eye segments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sight Sciences, Inc. is an ophthalmic medical device company, which focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. It operates through the Surgical Glaucoma and Dry Eye segments. The Surgical Glaucoma segment includes OMNI Surgical System for use in minimally invasive glaucoma procedures. The Dry Eye segment offers TearCare System and related components. The company was founded by Paul Badawi and David Y. Badawi in 2011 and is headquartered in Menlo Park, CA.

MENLO PARK, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the fourth quarter and full year ended December 31, 2023, after the market close on Thursday, March 7, 2024. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Sight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024

By tapping into the European market, Sight Sciences (SGHT) aims to capitalize on the growing demand for advanced eye care technologies.

Sight Sciences (SGHT) to Expand in Europe With New Launch

MENLO PARK, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced the launch of the Ergo-Series of the OMNI® Surgical System in Europe, a technology that facilitates surgeons' ability to perform minimally invasive, implant-free glaucoma procedures in adults with open-angle glaucoma.

Sight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter Meeting

MENLO PARK, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced the closing of an up to $65 million senior secured credit facility with Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”), a leader in customized debt financing for companies in life sciences and technology-related markets.

Sight Sciences Announces the Closing of up to $65 Million Senior Secured Credit Facility with Hercules Capital

MENLO PARK, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today reported preliminary, unaudited financial highlights for the fourth quarter and full year ended December 31, 2023.

Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Highlights

Decision ensures continued access to comprehensive outflow procedure enabled by OMNI® Surgical System technology for glaucoma patients Decision ensures continued access to comprehensive outflow procedure enabled by OMNI® Surgical System technology for glaucoma patients

Sight Sciences Announces Withdrawal of Final LCDs on Micro-Invasive Glaucoma Surgery from Five Medicare Administrative Contractors

Interventional eyelid procedures enabled by TearCare technology successfully delivered clinically and statistically significant improvements in every sign and symptom measured at every time point through six months Interventional eyelid procedures enabled by TearCare technology successfully delivered clinically and statistically significant improvements in every sign and symptom measured at every time point through six months

Sight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease

Prospective, long-term trial results are consistent with the significant body of published clinical evidence demonstrating the durable safety and effectiveness of procedures enabled with the OMNI Surgical System technology

Sight Sciences Announces the Acceptance for Publication of GEMINI 2, a Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant IOP and Medication Reductions Enabled with the OMNI® Surgical System Technology

Chevron

Hall of Fame Resort & Entertainment

OPAL Fuels Inc

Exxon Mobil

This article is an excerpt from the InvestorPlace Digest newsletter. To get news like this delivered straight to your inbox, click here.

5 Risky Stocks to Buy Immediately, According to AI

Sight Sciences, Inc. (NASDAQ:SGHT ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Philip Taylor - Investor Relations, Gilmartin Group Paul Badawi - Founder and Chief Executive Officer Ali Bauerlein - Chief Financial Officer Matt Link - Chief Commercial Officer Conference Call Participants Margaret Kaczor - William Blair Kallum Titchmarsh - Morgan Stanley Thomas Stephan - Stifel Operator Ladies and gentlemen, thank you for standing by. Welcome to the Sight Sciences' Third Quarter 2023 Earnings Results Call.

Sight Sciences, Inc. (SGHT) Q3 2023 Earnings Call Transcript

MENLO PARK, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today reported financial results for the third quarter ended September 30, 2023 and withdrew its guidance for full year 2023.

Sight Sciences Reports Third Quarter 2023 Financial Results and Withdraws Guidance for Full Year 2023

MENLO PARK, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced it will report financial results for the third quarter ended September 30, 2023, after the market close on Tuesday, November 7, 2023. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Sight Sciences to Report Third Quarter 2023 Financial Results on November 7, 2023

The event will include a presentation from Brandon Ayres, MD, Wills Eye Hospital and Sight Sciences executive management team on the successful six month results of the SAHARA head-to head randomized controlled clinical trial comparing TearCare® to Restasis® for the treatment of dry eye disease The event will include a presentation from Brandon Ayres, MD, Wills Eye Hospital and Sight Sciences executive management team on the successful six month results of the SAHARA head-to head randomized controlled clinical trial comparing TearCare® to Restasis® for the treatment of dry eye disease

Sight Sciences to Host SAHARA 6 Month RCT Results Reception at the American Academy of Ophthalmology 2023

Sight Sciences Announces Presentation of Successful Phase I Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease at the American Academy of Optometry Annual Meeting

Efficacy of the Three Most Commonly Used MIGS Technologies plus Cataract Surgery and Cataract Surgery Alone Were Evaluated and Compared in over 100,000 Glaucoma Patient Eyes Efficacy of the Three Most Commonly Used MIGS Technologies plus Cataract Surgery and Cataract Surgery Alone Were Evaluated and Compared in over 100,000 Glaucoma Patient Eyes

Sight Sciences Announces New, Large-Scale MIGS Data from 41st Congress of ESCRS Demonstrating TCOR™ Using OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma

Scilex Holding Co

Tenaya Therapeutic

Turnstone Biologics Corp

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 4 Health Care Stocks That Could Lead To Your Biggest Gains In Q3

Sight Sciences Inc.'s stock SGHT, +6.03% tumbled 32% premarket Tuesday, after the eyecare technology company issued a revenue warning, saying it's seen fewer Surgical Glaucoma new accounts in the third quarter amid reimbursement uncertainty. The Menlo Park, Calif.

Sight Sciences' stock tumbled 32% premarket after revenue warning

MENLO PARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced third quarter 2023 revenue guidance and updated its revenue guidance for full year 2023.

Sight Sciences Provides Revenue Guidance for the Third Quarter of 2023 and Updates Revenue Guidance for Full Year 2023

Former NuVasive President helped scale high growth medical device company to over $1 billion in revenue Former NuVasive President helped scale high growth medical device company to over $1 billion in revenue

Sight Sciences Appoints Matt Link as Chief Commercial Officer

MENLO PARK, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced plans to present at the upcoming Morgan Stanley 21st Annual Global Healthcare Conference in New York, NY.

Sight Sciences to Present at the Upcoming Morgan Stanley 21st Annual Global Healthcare Conference

Sight Sciences' Q2 2023 financial performance came in above Wall Street analysts, and SGHT's stock price rose by +7.6% last Friday following its results announcement. SGHT's key markets, glaucoma and dry eye, have addressable markets worth billions of dollars. I retain a Buy rating for Sight Sciences, as its above-expectations second quarter results give me the confidence that SGHT can realize its full growth potential in time to come.

Sight Sciences: Staying Bullish After Q2 Results Beat

Sight Sciences, Inc. (NASDAQ:SGHT ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Philip Tailor - Investor Relations Paul Badawi - Co-Founder & Chief Executive Officer Ali Bauerlein - Chief Financial Officer Tom Huang - Head of Corporate Strategy Conference Call Participants Craig Bijou - Bank of America Thomas Stephan - Stifel Operator Good day, and thank you for standing by. Welcome to the Sight Sciences Second Quarter 2023 Earnings Conference Call.

Sight Sciences, Inc. (SGHT) Q2 2023 Earnings Call Transcript

MENLO PARK, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today reported financial results for the second quarter ended June 30, 2023 and reaffirmed guidance for full year 2023.

Sight Sciences Reports Second Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023

The mean of analysts' price targets for Sight Sciences, Inc. (SGHT) points to a 44.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Predict a 44.19% Upside in Sight Sciences, Inc. (SGHT): Here's What You Should Know

Dry eye has significant negative impact on visual function including reading, driving, workplace productivity, physical functioning, and quality of life, and creates a substantial burden to patients and society in general² Dry eye has significant negative impact on visual function including reading, driving, workplace productivity, physical functioning, and quality of life, and creates a substantial burden to patients and society in general²

Sight Sciences Announces Positive Results and Primary Endpoint Successfully Met in SAHARA, a Randomized Controlled Clinical Trial Comparing Interventional Eyelid Procedures Enabled by TearCare® Technology to Restasis¹ for the Treatment of Dry Eye

News for Sight Sciences Stock (SGHT)